Biocom Lifelines - Spring 2012

Spring 2012

LifeLines 4

For the Southern California Life Science Community

Cover Story: Life Science Industry Primed for Growth

9 Public Policy: BIOCOM

Brings Key Regulators to

Southern California

11 Capital Development:

Helping Companies Find the Money 12

CROs‌Do Business Locally

Cover Image: Beautiful San Diego in Bloom.

volume 21 | issue 2

There’s a

Reason…

Local innovators have trusted Cushman & Wakefield’s Life Sciences Practice Group to provide their real estate needs for the past 30 years.

It’s because we have a deep understanding of the drivers associated with scientific discovery and we have a demonstrated track record of delivering exceptional results for our clients. That’s why year in and year out, we negotiate over 65% of all San Diego lab transactions.

65

%

There’s a reason more clients choose

C&W Global Life Sciences Practice Group over any other brokerage team.

How much does your broker know about Lab Real Estate?

Life Sciences Tenant Representation

By Transaction Value Past Three Years

C&W Life SCienCeS JLL Hughes Marino CBRE Cassidy Turley Studley Cresa Colliers

C&W Global life SCienCeS PraCtiCe GrouP The Science of Negotiating.

sdlifesciences.com

(858) 452-6500

Brent Jacobs

Greg Bisconti

Ted Jacobs

CA License No. 791657

CA License No. 1167920

CA License No. 1855220

President’s

Message

by JOE PANETTA President and CEO, BIOCOM

Our Southern California life science community has demonstrated its staying power, remaining vibrant despite the economic downturn. In this issue of LifeLines, I am pleased to share a new BIOCOM report on employment, corporate and academic diversity and the financial impact of our work. It’s an amazing story, built on three decades of consistent growth. Over the years, a handful of start-ups evolved into one of the largest life science clusters in the world.

As our members face continuing challenges from Congress and the FDA, I have been working with BIOCOM’s public policy team, company representatives and national partners to ensure that our voice is being heard at all levels of government. In fact, we have hosted senior FDA officials – Center for Devices and Radiological Health director Dr. Jeffrey Shuren, deputy commissioner for Medical Products and Tobacco, Dr. Stephen Spielberg and director of the Office of Patents and Trademarks, David Kappos—to discuss a wide range of issues. Most recently, BIOCOM hosted a roundtable discussion with FDA Commissioner Margaret Hamburg and a small group of CEOs. The discussion centered around the continuation of industry working together with the FDA to impart change and forge a better working relationship. We have continued to lobby our California delegation to repeal the harmful medical device excise tax and support legislation to expedite new drug approvals and modernize the FDA. BIOCOM has been very active in China, co-hosting conferences and signing significant agreements with economic development and life sciences organizations in key cities. We recently partnered with BIOCOM member company HUYA Biosciences to promote collaborations between Southern California and Chinese companies. In this issue, you will hear from David Jiang, managing director of our new BIOCOM China consulting arm. He will detail five myths of doing business in China, building our understanding of the Chinese life science market.

Also in this issue, we show you how to build your company dream team, acknowledge our Capital Development Committee’s successful efforts and describe our contract research and manufacturing community’s explosive growth. On the education front, we highlight the BIOCOM Institute’s collaborative efforts to develop new training programs, as well as partnering to create a new home for the San Diego Science and Engineering festival.

Meeting with many of our executives over the past few months, I am encouraged by their vision, optimism and dedication to accelerating our cluster’s scientific and technological innovation. This year, we will develop a bold, new strategic plan that integrates our strong foundation with our ongoing search for competitive opportunities. I look forward to working with all of our members to continue our successful efforts to improve lives.

www.biocom.org

In This Issue 4

Cover Story: Life Science Industry Primed for Growth

20 BIOCOM Asia Initiative: Five Myths about Doing Business in China

6

BIOCOM in Action: BIOCOM Hosts FDA Visits

22 Premium Member Spotlights AIS, Alexandria, BioSpace, Conatus Pharmaceuticals, Foley & Lardner LLP, Goodwin Procter

Editor: Jennifer Landress COPY Editor: Josh Baxt layout: Arlene Arreola Design: Mentus Inc.

25 BIOCOM Board and Committees

Volume 21, Issue 2

26 BIOCOM Membership

Please send a change of address or subscription request to Katelyn Doyle at kdoyle@biocom.org.

13 Medical Device Update: Fostering Growth And Education In Southern California’s Med Tech Industry 14 Members in Action: Global Life Science Partnering Conference, CALBIO 2012 19 Purchasing Group: Good Golf for a Good Cause

C o ve r S t o r y

Life Science Industry Primed for Growth As we enter spring, it has become obvious that the Southern California life science industry is primed for growth. Virtually every recent economic indicator has been positive: grants awarded, venture capital distributed, jobs created. By all accounts, the industry is thriving.

A recent BIOCOM report highlighted these positive trends.

Universities, hospitals, small businesses and other institutions received 2,053 grants from the National Institute of Health, totaling $977 million in 2011—up from $966 million in 2010.

The report also showed that employment remains stable and is projected to increase. Life science

By M o nica May, Ru s so Part ners Torrey Pines Mesa, a world-renowned center for life sciences is the home to many groundbreaking scientific research and life science companies and is the hub of the ever growing life sciences community in San Diego.

4 BIOCOM LifeLines Spring 2012

companies are expected to add more than 6,000 jobs in the next two years. In addition, 94 percent of the job growth is driven by Southern California’s unique strengths, such as our high concentration of research institutions.

The report also showcases the diverse makeup of the Southern California life science industry in San Diego, Orange, Riverside and Imperial Counties. In addition to its dense cluster of world-class academic institutions, San Diego County boasts a large number of research and lab service facilities, as well as a growing device and diagnostics industry.

Further north, in Orange County, the region has become a hub for medical device and diagnostics companies.

Looking further east, the number of life science companies in Riverside County continues to grow, especially in the medical device and diagnostics sectors. The county’s research sector is also expected to receive a significant boost in the very near future. Scheduled to open in 2013, The School of Medicine at the University of California, Riverside, like its counterpart at UC San Diego,

will act as a catalyst for expanding life science ventures in the region.

Imperial County is also experiencing growth in emerging industries, such as biofuels, which capitalize on the county’s agricultural roots.

Big Pharma: A Strong and Growing Presence Beyond the economic impact report, the increased presence of large pharmaceutical companies, such as Merck, Johnson & Johnson and AstraZeneca, is also spurring growth. Merck recently launched the California Institute for Biomedical Research (Calibr) in San Diego, committing $90 million to fund translational research for the next seven years. Calibr is being led by Peter G. Schultz, Ph.D., a worldrenowned chemist at The Scripps Research Institute, one of a cluster of non-profit biomedical research facilities on Torrey Pines Mesa.

“The decision to locate Calibr in San Diego was based in part on the proximity to several worldclass research facilities, including The Scripps Research Institute, Salk Institute, Sanford-Burnham

Medical Research Institute, La Jolla Institute for Allergy & Immunology and the University of California, San Diego, in addition to a large pool of talented scientists,” said Jim Schaeffer, executive director of external scientific affairs at Merck Research Labs.

In addition, Johnson & Johnson Pharmaceutical Research and Development recently opened Janssen Labs at San Diego, which will provide laboratory space for emerging life science companies.

“There are many elements involved in forming a life science company and housekeeping activities, such as finding laboratory equipment and ordering supplies, can shift the focus from the goal of delivering innovative healthcare solutions,” said Melinda Richter, CEO of Prescience International, which supported the development of Janssen Labs. “The model of Janssen Labs is one of capital efficiency—providing state-of-theart laboratory space, common core research facilities and office equipment— where entrepreneurs can accelerate their discoveries into the next generation of patient care.

The San Diego region is rich with researchers investigating novel technologies and therapeutics, so we knew this was an area where the center would really have a positive impact.”

Big Pharma Offers Key Exit Opportunities Large pharmaceutical companies offer other economic opportunities for life science companies, such as partnerships, licensing deals and mergers and acquisitions.

These exit opportunities have become especially important as the IPO market has cooled. Currently, partnering activity in the region is strong. Big pharma partnerships and acquisitions of San Diego life sciences companies in 2011 were valued at more than $3.6 billion, with upfront payments totaling $2.1 million.

A notable example of big pharma activity was AstraZeneca’s purchase of San Diego-based Ardea Biosciences for $1.26 billion in April. This is the pharmaceutical company’s largest acquisition in the past five years and demonstrates pharma’s high level of interest in local biotech companies. Ardea’s lead therapeutic candidate, called lesinurad, is a small molecule compound that treats the buildup of uric acid in patients with gout.

The drug is currently in Phase 3 development.

Mergers and acquisitions, as well as the growing number of technology accelerators in Southern California, are extremely promising developments and represent a

strong source of funding for the region. These activities are only expected to grow as pharma adopts a higher profile in our community. Also, with patent expirations looming, pharmaceutical companies will continue to have a profound need to refill their pipelines. These and other factors make the Southern California life sciences industry well-positioned to benefit from big pharma investment.

Increasing Venture Capital Investment Venture capital investment, both nationally and locally, is also increasing. According to BioWorld Today, $391 million was secured nationally in biotech venture rounds in the first quarter of 2012, a 34 percent increase over the first quarter of 2011. According to PwC Money Tree, Southern California venture funding for biotechnology and device companies increased by nearly $100 million in the first half of 2011. BIOCOM is building on this success and will continue to pursue increased VC investment.

“Southern California is attractive for venture capital investment due to the combination of three key factors: the wealth of scientific innovation in academic and independent research institutes; the growing track record and availability of experienced entrepreneurs and management; and the strong collaborative culture in our community,” said David Kabakoff, Ph.D., executive partner at Sofinnova Ventures, a venture capital firm focused on early-stage life science and information technology companies.

Life Science Synergy The future is bright for Southern California’s life science community. Anchored by a cluster of renowned research institutions, our biotechnology, pharmaceutical, medical device and diagnostics, industrial biotechnology, personalized medicine and sequencing companies give the region a unique competitive advantage and a strong foundation for continued growth.

As we embrace this growth, BIOCOM is committed to supporting the region’s life science companies through advocacy, networking conferences and group purchasing deals. We will also leave no stone unturned as we seek other initiatives to benefit our members. As the national and regional economies continue to expand, Southern California’s intellectual capital, collaborative mindset and innovative approaches will continue to keep our life science companies on the leading edge and help our community thrive.

BIOCOM LifeLines Spring 2012

5

BIO C OM i n Ac t i o n

BIOCOM Hosts FDA Visits

by Jimmy Jackson, Vice President of Public Policy, BIOCOM

As 2011 started, the BIOCOM board gave staff direction to attempt to help effect change at the FDA and forge closer relationships with senior FDA leadership. The Board recognized that, with user fee reauthorizations looming in 2012 for prescription drugs, medical devices and biologics, the coming few years would shape the future of the industry well into the next decade.

BIOCOM had already had a historical relationship with the FDA leadership through the ongoing survey series produced by PwC and BIOCOM, Improving America’s Health, A survey of the working relationship between the life sciences industry and FDA. Leveraging this relationship, BIOCOM began discussions with FDA leadership on the concerns its members had communicated. As a trade association, BIOCOM often can raise issues that individual companies are reluctant to voice on their own.

Joe Panetta, BIOCOM and Dr. Steven Spielberg of the FDA.

6 BIOCOM LifeLines Spring 2012

As a result of these discussions, BIOCOM has been able to play a role in bringing senior FDA officials to the Southern California community to discuss ways the industry can work with the FDA in order to achieve our mutual goals of delivering safe and effective therapeutics, devices and diagnostics to patients though a predictable, efficient and transparent regulatory process.

In January, 2012, BIOCOM hosted Dr. Jeffrey Shuren, director of the Center for Devices and Radiological Health and Dr. Steven Pollack, director of the Office of Science and Engineering Laboratories. Drs. Shuren and Pollack were taken on tours of member facilities in Orange and San Diego Counties, and had interactive discussion sessions in both regions.

In February, BIOCOM hosted a roundtable discussion with Dr. Steven Spielberg, deputy commissioner for medical products and tobacco. In

David Webb of Celgene, Margaret Hamburg of the FDA, and Jimmy Jackson of BIOCOM.

this very critical role, Dr. Spielberg oversees the centers for drugs, medical devices, biological products and tobacco. Dr. Spielberg met with companies working in the diagnostics and personalized medicine space about some of the unique regulatory challenges these companies are facing.

Most recently, in April of 2012, BIOCOM was honored to host a small roundtable discussion with Dr. Margaret Hamburg, Commissioner of the FDA. A cross section of BIOCOM’s membership was able to have a candid conversation with the Commissioner in an informal setting, the discussion ranging from accelerated approval pathways to regulatory science to ways in which the industry can partner with the industry to achieve a well-trained reviewer workforce.

BIOCOM’s membership was able to have a candid conversation with the Commissioner in an informal setting.

BSKB-BIOCOM-LifeLines-Ad.indd 1 BSKB-BIOCOM-LifeLines-Ad.indd 1

Client: Birch, Stewart, Kolasch & Birch, LLP (BSKB) ContaCt: Elizabeth Richards, riche@bskb.com, 703.205.8000 Client: Birch, Stewart, Kolasch & Birch, LLP (BSKB) ContaCt: Elizabeth Richards, riche@bskb.com, 703.205.8000 ae: Jeff Lupisella x225 PM: Jeff Lupisella x225 VeR. : 1/2 pg. hor bleed ae: Jeff Lupisella x225 PM: Jeff Lupisella x225 VeR. : 1/2 pg. hor bleed PRojeCt: BSKB-063 ‘12 BIOCOM LifeLines Ad Mod. date: 04.20.12 Fri 1:17 PM PRojeCt: BSKB-063 ‘12 BIOCOM LifeLines Ad Mod. date: 04.20.12 Fri 1:17 PM Run date: Spring 2012 Pub: LifeLines/BIOCOM 4CP: n n n n Size: 8.75” x 5.25” Run date: Spring 2012 Pub: LifeLines/BIOCOM 4CP: n n n n Size: 8.75” x 5.25” Confidential: Information contained within this document is only intended for the recipient. Copying, distribution or communication of this document is stricly prohibited.

Confidential: Information contained within this document is only intended for the recipient. Copying, distribution or communication of this document is stricly prohibited.

13221 Woodland Park Rd., Suite 420, Herndon, VA 20171 tel 703.437.8018 fax 703.437.8268 vizual.com 13221 Woodland Park Rd., Suite 420, Herndon, VA 20171 tel 703.437.8018 fax 703.437.8268 vizual.com

8 BIOCOM LifeLines Spring 2012

4/20/12 1:18 PM 4/20/12 1:18 PM

P u b l i c P o l i cy Up d a t e

BIOCOM Brings Key Regulators to Southern California

by Jimmy Jackson, Vice President of Public Policy, BIOCOM

This year got off to a rousing start, as B I O C O M hosted two senior FDA leaders: Dr. S t e p h e n Spielberg, d e p u t y commissioner for Medical Products and Tobacco and Dr. Jeffrey Shuren, director of the Center for Devices and Radiological Health; as well three senior members of the USPTO, including director David Kappos.

More recently, as is noted elsewhere, BIOCOM hosted FDA commissioner Margaret Hamburg. As the year progresses, we look forward to bringing more decision-makers from Washington to Southern California.

Speaking of Washington, the next few months will be critical for our industry, as prescription drug and medical device user fee authorizations are due to expire. Historically, Congress is more inclined to make changes to the drug and device approval process, post-market surveillance and disclosures during this window.

BIOCOM has been active, working with Congress and Food and Drug Administration staff to build a more transparent and predictable FDA. We

are collaborating with our national partners at BIO, AdvaMed, PhRMA, and MDMA, as well as regional partners CHI and BayBio, to present a common front. Stay tuned to Biocommunique, as events can move rapidly and your engagement is essential.

In addition, as the USPTO continues to proceed with rulemaking for the America Invents Act (patent reform), BIOCOM will provide information for our members and comment to the agency as warranted.

The USPTO has been reaching out to the industry and making regular information trips to Southern California. We encourage you to participate in our sessions with USPTO representatives.

On the state level, a bill (AB 1277) co-sponsored by BIOCOM, BayBio and CHI to reduce duplicative state inspections continues to move forward. Governor Jerry Brown, during his speech at BIOCOM and BayBio’s CALBIO 2012, noted he is already taking a long look at this legislation. Crafted with significant input from BIOCOM members, the bill is on track for another legislative hearing in late spring. We are cautiously optimistic.

On the local level, I am pleased to announce that BIOCOM recently

endorsed Assemblyman Nathan Fletcher for Mayor of the City of San Diego. A committee of BIOCOM board members interviewed all four major candidates and overwhelmingly recommended Assemblyman Fletcher, who has worked closely with the life science industry. The life science industry plays a critical role in his vision for San Diego, and Assemblyman Fletcher has the energy and enthusiasm to bring San Diegans together to make this happen. We look forward to working with him to make our shared vision of San Diego as the country’s Most Innovative City a reality.

BIOCOM LifeLines Spring 2012

9

Premier Supplier in the Purchasing Group Member of

Cleanroom Laundry Services

www.pcs-clean.com ISO 9001:2008 CERTIFIED - High Density Esd Garments for Sterile & Non Sterile Applications - ESD Coveralls, Knee High Boots & Hoods - NFPA 70E FR Garments - Frocks - Shoe Covers - Sterile Goggles - Face Mask - Mops

Since 2002, Prudential Cleanroom Services / Prudential Overall Supply continues to provide BIOCOM Members reusable textile products and services for rental, lease and direct purchase programs. visit us @ www.pcs-clean.com and www.pos-clean.com

Uniforms U if if and d Textile T til Rental R t l Programs P

www.pos-clean.com - Work Wear Pants, Jeans and Shorts - Protective/Fire Retardant and Hi-Visibility Apparel - Executive and Career Apparel Shirts and Pants - Consumable Supplies: Restroom and Non-Restroom - Towels, Reusable Linen Napkins - Tools, Stands & Lockers - DIRECT SALE MERCHANDISE - Nike, Ogio and more!

- Cover Garments - Food Service Apparel - Medical Apparel - Casual Wear Apparel - Jackets & Vests - Mats - Mops

Cleanroom Contact: Rosa Vasquez, PCS/ BioCom Account Executive RosaV@pos-clean.com OfďŹ ce 323.722.0636 / Direct 626.848.9785 REUSABLE TEXTILES

GU E ST C OMM E NTAR Y

Helping Companies Find the Money

by Carin Canale-Theakston, President, Canale Communications Inc. Co-Chair, BIOCOM Capital Development Committee Perhaps the most common demand from life s c i e n c e entrepreneurs is: Show Me The Money.

The B I O C O M Capital Development committee’s goal is to help Find Them The Money.

In other words, attract more investment for our member companies and Southern California as a whole.

We are working aggressively, continuing our successful Venture Capital (VC) Day and launching new programs, such as Pharma Partnering Days and The Pitchers Club.

During VC Days, we invite out-oftown firms with proven life science investment track records to San Diego to meet with select companies. We work closely with the VCs to identify their top interests: company focus, stage of company and assets, size of financing and other factors. We want to make the VCs’ trip as rewarding as possible.

I am pleasantly surprised by how easy it is to find enthusiastic VCs, from coast to coast, who are eager to spend a day with our companies.

They believe the region is an innovative hub and are grateful to BIOCOM for spearheading this effort.

The first of three VC Days, held on April 25, focused on corporate VCs. Seven companies presented one-on-

Entrepreneurs made dress rehearsal one to managing partners from pitches to a group of seasoned MedImmune Ventures, SR1 (the decision-makers.

Four brave GSK venture group) and Astellas companies participated in the event Venture Management. and all had positive responses. One Similar to VC Day, BIOCOM is entrepreneur noted that the feedback launching the Pharma Partnering he received has already been Day program. BIOCOM member incorporated into his pitch. companies can meet one-to-one with Companies interested in business development and licensing participating in VC Days, Pharma team representatives from large Partnering Days or Pitcher’s Club pharmaceutical companies. The first should contact Jennifer Landress at program is a joint function with jlandress@biocom.org.

BayBio on May 16 in San Francisco.

Representatives from Bayer China are interested in companies with phase II-through-marketed therapeutics in cardiovascular disease, diabetes, oncology, neurology and respiratory, gastrointestinal and infectious disease.

Companies can explore opportunities in China A recent BIOCOM Investor Roundtable focused on Corporate VCs with over 35 and other Asian markets.

CEOs in attendance. VC panelists included On May 17-18, Sakae Asanuma from Astellas Venture representatives from Management, Simeon George from SR1/GSK Bristol-Myers Squibb will and Sam Wu from MedImmune Ventures. meet with local biotechs The panel was moderated by Carin CanaleTheakston of Canale Communications. with programs that These roundtables are one of the many complement the initiatives the Capital Development company’s pipeline. In committee is focused on. addition to Bayer China and BMS, we anticipate holding at least one additional Partnering Day this year.

Finally, the BIOCOM Pitcher’s Club debuted on March 27.

BIOCOM LifeLines Spring 2012

11

M E MB E RSHIp Up d a t e

CROs‌Do Business Locally

by Kira Jenkins, Director of Membership, BIOCOM Have you noticed the vast array of services our local contract r e s e a r c h organizations (CROs) provide?

BIOCOM is working hard to assist this growing sector, and we hope that Southern California life science companies will look to their neighbors first before going outside our community to do business.

CROs have evolved into much more than low cost service providers. They have increasingly become valuable partners for life science companies, providing crucial expertise essential to accelerating drug development. It’s this evolution that is driving the growth of local CROs. In June, BIOCOM will launch a new CRO website (www.biocomcro. org), so companies can easily find the local CRO that best meets their needs.

The website will feature a comprehensive CRO directory, a drug development guide outlining each phase of a trial and the CROs that can be of assistance. A resource section will also be available for companies to access a set of best practices, FAQs and presentations from our CRO educational event series.

BIOCOM will be holding its first annual Interactive Pharmaceutical Outsourcing Workshop in September.

12 BIOCOM LifeLines Spring 2012

Attendees will work together in small groups, discussing outsourcing strategies, legal and regulatory prerequisites issues, partnerships, offshoring to re-shoring and more.

To learn more about our CRO initiative, or to get involved, please contact Kira Jenkins at kjenkins@ biocom.org or call 858.455.0300 x117.

BIOCOM CRO Members Absorption Systems Accelagen Accelovance Accugent Laboratories Acurian Advantar Laboratories Agility Clinical Althea Technologies Ambit Biosciences American Peptide Company AMRI AnaBios Corporation Annova Chem Aptuit Asterand Behavioral Pharma Bend Research BioAtla Biologics Process Development BioTox Sciences Califia Bio Cato Research Celula ChemDiv Concortis Biosystems Davos Chemical EastHorn Clinical Services eStudySite Exon BioSystems Explora BioLabs Genoptix

Hamari Chemical HungaroTrial CRO Huntingdon Life Sciences Invetech IriSys JadeBio MedinCell MicroConstants Millenium Laboratories Molecular Response Neox CRO NeurAccel Biosciences NexMed Nexus Oncology Novella Clinical Pacific World Discovery PacificGMP Pharmatek Laboratories Prescos Profil Institute For Clinical Research PSI CRO Puracyp Quadrants Scientific RetroVirox SAFC Pharma Sherpa Clinical Packaging Siloam Biosciences Sparta Systems Stemgent Synteract Tioga Research Toxikon Triligent International Trius Therapeutics Ultimate Labs Velesco Pharmaceutical Services Zenobia Therapeutics Zyagen

M E DI C AL D E V I C E U P DAT E

Fostering Growth And Education In Southern California’s Med Tech Industry

by Joleen Schultz, Principal, 321 Medical Launch Co-chair, BIOCOM Medical Device & Diagnostics Committee The Medical Device and Diagnostic industry is thriving in S o u t h e r n California and BIOCOM is committed to furthering medical technology innovation by focusing on initiatives that support the companies responsible for these advancements.

BIOCOM events provide a collegial environment to facilitate technology convergence and professional networking that is important to medical device and diagnostic member companies. Two upcoming annual events, in particular, reflect this commitment to positively influencing the region’s med tech community by celebrating new technologies, bringing members together and providing the current information necessary to move the local industry forward.

The 2012 Medical Device and Diagnostics Expo on May 15th is an event where the region’s leading medical device and diagnostic companies can showcase their latest technology innovations to more than 200 industry influencers, funding sources, potential business partners and media. The event will feature new technology from over 15 companies, and from these an

esteemed panel of judges will select five companies for special recognition in the areas of technical excellence and medical significance. Local firms that provide design and contract manufacturing services for device and diagnostic companies, venture capitalists, and hospital decision leaders will also be in attendance, making this an ideal networking opportunity. The Expo is focused on creating awareness around new technologies and celebrating the future of med tech. Companies with a new healthcare product that is either currently under development or has launched within the last two years will be on hand to demonstrate their innovations and answer questions.

DeviceFest 2012, the second upcoming annual BIOCOM med tech event, is one of the largest medical device conferences in Southern California. Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiologic Health, was the keynote speaker at last year’s conference. Dr. Shuren provided updates regarding ongoing changes and improvements at the FDA, as well as solicited suggestions and critiques from conference attendees. This year’s DeviceFest is shaping up to be equally informative and valuable.

On August 21st, the medical device and diagnostic community will gather in Orange County for the full day

conference that includes keynote presentations, panel discussions and workshops. The panels of industry experts will be discussing key issues in med tech today, such as regulatory, r e i m b u r s e m e n t , a n d commercialization. This is an education-focused event created to help medical device companies move their products successfully through the development and regulatory processes to commercialization. With over 200 key life science professionals in attendance, there will be ample opportunities for networking throughout the day and during the closing cocktail reception. For more information on DeviceFest, visit www. biocom.org/event/index/DF_2012.

BIOCOM also offers numerous educational quarterly events and workshops, as well as networking opportunities for the region’s medical device and diagnostic industry. Be sure to check out the events page at www.biocom.org for a listing of upcoming activities.

BIOCOM LifeLines Spring 2012

13

Members in Action > Global Life Science Partnering Conference

Networking is a key element of this conference. The intimate setting allows for plenty of opportunities to chat wth the top deal makers.

Karen Bernstein of BioCentury and Joe Panetta of BIOCOM

T h e 2 n d A n n u a l B I O C O M G l oba l L i f e S ci e n c e P a rt n e r i n g C o n f e r e n c e was an exclusive global partnering and networking forum that brought together senior executives and business development professionals from leading pharmaceutical and biotech companies. The conference included highly interactive panel discussions, individual company presentations, one-on-one meetings and numerous networking opportunities.

This event continues to be a great venue to showcase the impressive accomplishments and progress taking place in one of the top biotech hubs in the world.

Photos by JT MacMillan Photography

Our evening Reception was held at the Evans Garage. It was a unique opportunity to visit a world class private collection of vintage automobiles in a beautiful and whimsical setting.

14 BIOCOM LifeLines Spring 2012

Corporate Strategy Panel with Tony Rosenberg of Novartis Pharma Ag, George Golumbeski of Celgene Corp, Brian McVeigh of GlaxoSmithKline Pharmaceuticals, Marty Birkhofer of Bristol-Myers Squibb and Greg Wiederrecht of Merck & Co.

Company Creation Panel with Dan Burgess of Rempex Pharmaceuticals, Faheem Hasnain of Receptos, Inc., Laura Shawver of Cleave Biosciences, Karen Bernstein of BioCentury and Patrick Mahaffy of Clovis Oncology.

Members in Action > CALBIO

Joe Panetta of BIOCOM, David Webb of Celgene, Paul Hastings of OncoMed Pharmaceuticals, Jim Greenwood of BIO, Congressman Brian Bilbray and Gail Maderis of BayBio.

Remi Brouard of Sanofi-Aventis, Jim Schaeffer of Merck Research Labs and Christopher Haskell of Bayer Healthcare.

CA LB I O

For the first time, BayBio and BIOCOM organized a statewide meeting for California’s life science companies. CALBIO 2012:Driven by Patients was the first West Coast conference to bring together industry and disease foundations for successful, mutually beneficial discussions. Expert speakers addressed the pressing issues facing our industry today: patient access, risk and reform at the FDA, new business models and financing. CALBIO 2012 exemplified the strength of California as a model for life sciences innovation.

Gail Maderis of BayBio, Governor Jerry Brown and Joe Panetta of BIOCOM.

Photos by Walt Creative

Bryan Roberts of Venrock, Bob More of Fraizer Healthcare Partners, Jay Lichter of Avalon Ventures, and Carol Gallagher discuss life science innovation.

One of the plenary sessions which brought together conference attendees to hear provocative keynote discussions.

BIOCOM LifeLines Spring 2012

15

GU E ST C OMM E NTAR Y

Building Dream Teams

by Robin Toft, President and CEO of Sanford Rose Associates®

Great people build fantastic companies, and great leaders build exceptional teams.

Dream Teams field highperforming executives who surround themselves with the best. These A players supply vision, motivation and inspiration.

Yet, not all high level executives are A players capable of creating elite teams.

Building a dynamic Dream Team is challenging. Hiring officials must take a thoughtful look at their organization and commit to finding exceptional candidates in a sea of resumes, phone screens, on-site interviews, reference and background checks and competing offers. In addition, tackling an executive search in-house often distracts senior staff from managing and growing the business.

“When you engage and retain an executive search firm, it is not a matter of just putting an ad in the paper and seeing who the best person is that applies,” says Peter Felix, president of the Association of Executive Search Consultants. “At the senior executive 16 BIOCOM LifeLines Spring 2012

level, it’s crucial to find the best person you can. The whole purpose of proactive recruitment is to bring into consideration candidates that might not be otherwise identifiable in the market. They may not respond to an advertisement. It opens up a whole range of candidates who might not have been aware of or shown interest in your appointment.”

Many companies have experienced multiple failures finding key executives. Downtime costs money, as does hiring poorly. The amount of resources lost in poor hiring underscores the case for adding executive recruitment services to your budget. A bad hire can cost your company time, money and its competitive edge in the marketplace.

Sarah Kessler, author of How to Conduct a Job Interview, says: “The cost of a bad hire is steep, and it’s not just the wasted salary that’s expensive.

Severance payments, training time, potential customer problems are all items that you’d prefer to leave out of your budget. Many experts estimate that the cost of a bad hire exceeds the annual salary of a position.”

Life science companies face a shortage of A players capable of

building strong, engaged teams focused on growth. Strategicallyaligned management is crucial through all hiring phases—from the early search to on-boarding. We have often identified organizational issues that inhibit the company’s ability to hire the best. Identifying these issues, and working with our clients to resolve them, allows companies to attract elite talent.

I am part of a very real Dream Team. Let’s get started building your Dream Team.

Life Sciences Group

#1 in COMPLETED TRANSACTIONS FOR 2011 Cassidy Turley Life Sciences Group #2 Jones Lang LaSalle Life Sciences Group #3 Cushman & Wakefield Global Life Sciences

Affraxis Fabrus Genalyte Genewiz InhibRx

Amicus Therapeutics Nanoimaging Services Synthetic Genomics Institute

Ligand Advanced Ambrx BioHealing Epic Sciences Intellikine

#4 Hughes Marino #5 CBRE Life Sciences Group

Halozyme

DiscoveRx

Lpath PaxVax Pathway Genomics

Becton Dickinson UCSD

Bio-Edge

Sapphire Energy

LJ Bioengineering

aTyr Epic Sciences Sequenom

GNF Novartis Verenium

Cassidy Turley’s Life Sciences Group completed more lease transactions in 2011 than any other commercial real estate company in San Diego.

Celgene Cypress Bioscience

The Pavilion* Concorde*

*Sale Transactions

Dave Odmark

858.546.5430 dodmark@breb.com

Jerry Keeney

858.546.5489 jkeeney@breb.com

Brian Starck

858.546.5486 bstarck@breb.com

For a detailed list of our available lab space please visit our website at:

www.sdlabspace.com

Tenant Representation / Project & Development Services / Property Management / Corporate Services / Capital Markets / Project Leasing

SPACETO TO SPACE

DISCOVER University Science Center – East University University Science Science Center– –Court East East 3545-3575 JohnCenter Hopkins 3545-3575 3545-3575John JohnHopkins Hopkins Court Court San Diego, CA San SanDiego, Diego,CA CA

“We relocated our research and office facility from the Los Angeles area to “We “Werelocated relocatedour ourresearch researchand andoffice officefacility facilityfrom fromthetheLos LosAngeles Angelesarea areatoto Torrey Pines under a very compressed occupancy timeline. ey brought Torrey TorreyPines Pinesunder undera avery verycompressed compressedoccupancy occupancytimeline. timeline.ey eybrought brought all of the pieces together for us – leasing, construction, property allallofofthethepieces piecestogether togetherforforusus– –leasing, leasing,construction, construction,property property management and facilities. We expected our real estate partner to meet management managementand andfacilities. facilities.We Weexpected expectedour ourreal realestate estatepartner partnertotomeet meet our needs, but the BioMed Realty team really exceeded our expectations.” our ourneeds, needs,but butthetheBioMed BioMedRealty Realtyteam teamreally reallyexceeded exceededour ourexpectations.” expectations.”

Peter Klemm, Chief Executive Officer Peter Peter Klemm, Klemm, Chief ChiefExecutive ExecutiveOfficer Officer For more information on how BioMed Realty can develop exceptional environments for your company, For For more more information information onon how how BioMed BioMed Realty Realty can can develop develop exceptional exceptional forfor your your company, company, please contact Chris Elmendorf or Tracy Murphy at (858) 485-9840environments orenvironments visit www.biomedrealty.com. please please contact contact Chris Chris Elmendorf Elmendorf oror Tracy Tracy Murphy Murphy atat (858) (858) 485-9840 485-9840 oror visit visit www.biomedrealty.com. www.biomedrealty.com.

P u r c h a s i n g g r o u p Up d a t e

Good Golf for a Good Cause

by Rick Fultz, Managing Director, BIOCOM Purchasing Group

On April 2, 136 golfers assembled at the b e a u t i f u l Santaluz Golf Club to tee-up, network and support life s c i e n c e education. Created to raise awareness and support for the BIOCOM Institute, the event began with bagels, Bloody Marys, putting and pitching contests and a trick shot exhibition by professional long-drive champion Vincent “The Pasta Man” Ciurluini.

After picking their jaws up from the trick shots, players headed to the pristine course, where they were treated to contests, characters and a challenging day of golf. The Pasta Man met everyone at the 13th tee with a pleasant surprise. Instead of facing the daunting 530-yard uphill par 5 on their own, they got to watch Ciurluini happily blast a 350+ yard drive for each group to help kick-start their scorecards.

A special thanks to the Sharpshooter ladies from Sharp Business Solutions, who provided homemade Sharp Jello shots. We would also like to thank Casanova fish tacos for the delicious snacks and Lost Abbey and Stumble Foot breweries for providing some of

Southern California’s finest local beers.

While most players were happy to be a part of the fun, some meant business. Jeff Carbaugh, Ernie Hahn, Reid Marquand and Matt Sherril claimed first place with a 55. David Hale, Garrett Hale, Bob Jones and Taylor Massey placed second. Rich McGonniga, Gene Smallwood, Ryan White and Matt Wiener finished third. The foursome from BP Biofuels won the coveted “Dead-Ass-Last” trophy, proving they are hard at work creating cleaner energy—not hiding on the golf course.

The contest winners were also rewarded for their triumphs. Nick Araiza and Marta Hawkins won the “Whack the Quack” contest, in which players try to hit a rubber duck for distance. Scott Durall won the pitching contest. Rich McGonniga won closest to the pin. Juan Londono won the straightest drive and Jerry Jackson won the putting contest.

Throughout the day participants bid on silent auction items ranging from a Sharp flat screen TV, Chargers and Padres memorabilia, VIP tickets to the U.S. Open and other unique packages. The event netted more than $35,000, for the 501c3 Institute.

“It is amazing to see the life science community mobilize to support the

next generation of life science leaders,” said Kristie Grover, Executive Director of the BIOCOM Institute. “The mission of this charity golf tournament is to raise awareness of the BIOCOM Institute. Proceeds help expand the science education and workforce development opportunities offered to students, teachers and workers throughout Southern California.”

BIOCOM LifeLines Spring 2012

19

BIO C OM ASIA I n i t i a t i ve Up d a t e

Five Myths about Doing Business in China

by David Jiang, Managing Director, BIOCOM China Consulting China is growing fast, as is its demand for W e s t e r n products. Since 2000, US exports to China have grown 468 percent. At $92 billion in 2010, China is now America’s third largest export market. In 2010, General Motors sold more light vehicles in China than it sold in the U.S. At the end of October 2011, Starwood had 84 hotels in China and was planning 100 more.

It’s not too late to enter China, but several myths must be dispelled first.

Myth 1: Companies go to China for cheap labor.

Western companies have benefited greatly from cheap labor in China.

However, cost savings is no longer their primary motive. Companies move to China for speed-to-market and access to talent. Most importantly, companies gain access to a large, rapidly growing market.

China is already the world’s largest auto market, largest cell phone market, second largest luxury market and the third largest pharmaceutical market. New business models target the growing middle class, adding Made for China to Made in China.

Myth 2: Most people in China cannot afford, and do not want, Western medicine.

In the next decade, as many as one billion Chinese will be middle class.

With this economic growth, people are demanding top quality medicines and products. In addition, the Chinese Central government committed more 20 BIOCOM LifeLines Spring 2012

than $120 billion in 2009 to provide healthcare in rural areas. With this government help, more people have access to Western medicine. In addition, Western brands are perceived to be high quality, trustworthy and effective.

Myth 3: The Chinese do not Innovate We are seeing a major shift from Made in China to Discovered in China. The government is investing $308 billion in science and technology.

In addition, many highly educated, Western-trained professionals are returning China to embrace better career opportunities. They are starting innovative companies and developing new products.

Many Chinese companies are no longer satisfied selling traditional Chinese medicines and generics.

These companies are actively seeking partners in the West to co-develop innovative medicines. In the U.S., biotech companies are searching for partners to provide much-needed capital for basic research and clinical trials. U.S. companies can find Chinese partners to share R&D costs and co-develop new products. The Chinese partner earns the commercial rights in China, while the U.S. company retains global rights outside of China.

Myth 4: There is little intellectual property protection in China Since China joined the WTO in 2001, intellectual property (IP) protection has expanded significantly.

While Chinese IP protection can definitely improve, the government

has made concrete and deliberate efforts. Many leading pharmaceutical companies have increased their research investment in China. In addition, because of their own innovation and acquisition of Western technologies, Chinese companies place a greater value on IP protection.

In 2010, China filed 12,339 patents, the fourth highest under the Patent Cooperation Treaty, a 56 percent increase over the previous year.

Myth 5: Western business logic can be applied to China Although many Western business principles can be applied to China, not everything is transferable. For example, the patent cliff is far less severe after patent expiration. For example Glucobay, Bayer’s off-patent drug, only sold $12-15 million in the U.S. in 2010, but reached $283 million in China. Due to Chinese preferences for Western brands, many pharmaceuticals continue to do well after the patent expires.

The Bottom Line There are many opportunities in China, but companies must proceed with care, patience and persistence. In addition to industry-specific risks, such as product approvals from regulatory authorities, there is inflation, the real estate bubble, labor unrest, growing disparities between the rich and poor and other challenges.

Pick a trusted local team to navigate the terrain. The new experiences that come from doing business in China are what make the eventual success that much more rewarding.

BIO C OM INSTITUT E Up d a t e

Science Programs Unite

by Karen Overklift, Associate Director of Outreach and Enrollment, BIOCOM Institute Since 2008, the San Diego Festival of Science and Engineering has introduced kids and adults to antibodies and a n i m a l s , molecules and computers, green technologies and robotics. Last year, the Festival hosted 140 fascinating booths, allowing thousands of visitors to sample a full range of scientific inquiry. Since its inception, the Festival has been orchestrated by UCSD. But starting next year, the event will be managed by the BIOCOM Institute.

This is an excellent fit, as the Festival

and the BIOCOM Institute share common goals. The Institute’s K-12 programs promote STEM literacy to help students compete in these critical fields. The Festival unites San Diego’s technology community to engage kids and families in science and engineering.

The BIOCOM Institute and the Festival both strive to engage kids in STEM activities and to highlight how science and engineering impact people’s lives. Both provide interactive demonstrations, hands-on activities and engaging speakers to show diverse groups of students they can become leading scientists, engineers and innovators.

The BIOCOM Institute’s Science Education Speakers Bureau and

Career Chats bring volunteers from biotechnology companies to middle and high school classrooms to talk about their STEM careers and inspire students with hands-on activities. The Festival hosts a week of interactive demonstrations, dynamic speakers, culminating in an Expo Day, offering more than 27,000 attendees a range of STEM exhibits.

“We work with our partners to develop educational programs that enhance scientific literacy, making it an ideal fit with the mission of the San Diego Festival of Science and Engineering,” said Kristie Grover, Executive Director for the BIOCOM Institute. “We feel well-suited to take on and grow the Festival and its yearround focus on STEM education.”

BIOCOM LifeLines Spring 2012

21

Premium Member sPOTLIGHTS

•

A leading provider of provider of enterprise-class data center, cloud and connectivity services.

•

Well-established in the San Diego region (54% of market), with a disaster recovery focused data center in Phoenix.

•

Emphasis on secure, high availability facilities.

•

Systems and processes specifically for compliance to Life Sciences standards.

•

AIS is the “Gateway to the Cloud”

•

•

Founded in 1994, Alexandria owns approximately 15 million square feet comprising 170 properties worldwide.

•

Alexandria is dedicated to creating collaborative environments where the global life science community can come together to exchange ideas and foster innovation.

www.americanis.net

•

Founded in 2005 by former executive management team of Idun following Pfizer’s acquisition

•

Raised $60M in venture capital

•

Pipeline includes two clinical-stage drug candidates for HCV and liver fibrosis and several oncology assets

•

Acquired the Idun subsidiary from Pfizer in 2010

www.conatuspharma.com

22 BIOCOM LifeLines Spring 2012

Alexandria is the leading publicallytraded owner and operator of highquality, sustainable real estate and technical infrastructure for the broad and diverse life science industry.

•

BioSpace is the leading news and employment website for the life sciences.

•

More than 350,000 scientists, researchers, engineers and C-level executives visit BioSpace each month in search of news and employment opportunities. Eighty percent of those users return to the site are highly educated – 59% have a master’s degree or higher; 65% have 4+ years of experience.

•

BioSpace also powers the BIOCOM Career Center bringing members powerful job opportunities and driving highly qualified candidates to employer openings.

www.ARE.com

www.biospace.com

•

For 25+ years, Foley attorneys have helped life sciences companies meet business goals by melding legal and business insight in business, IP health care, and FDA regulatory law

•

850 attorneys serving clients through offices in Boston, Hong Kong, London, Los Angeles, New York, San Diego, San Francisco, Silicon Valley and Washington, D.C.

•

1,000 attorneys across 18 US offices and in Brussels, Tokyo, and Shanghai

•

•

Over 80 attorneys focused on the life sciences industry

Serving over 400 life sciences clients, from start-up through mature public company

•

•

Ranked #1 in client service and “best value” by 2010 BTI Client Service survey

Industry-leading and nationally recognized attorneys in the corporate, intellectual property, partnering, and regulatory fields

•

Established in San Diego in 2007

www.FOley.com

www.goodwinproctEr.com

The BIOCOM Golf Tournament

THANK YOU TO Our Sponsors 2012

BIOCOM Golf Tournament

2012

Sponsor: BIOCOM Lead Golf Tournament

Premium Sponsors:

Whack the Quack Sponsor:

Reception Sponsor:

FOOD & BEVERAGE SPNSORS:

INDIVIDUAL HOLE SPONSORS;

Hole-in-One Sponsors:

VWR

Accelerating Life Science Solutions in California

GLOBAL REACH, LOCAL SUPPORT. SINCE 1852.

VWR is a global leader in the distribution of laboratory products, supplies and services, offering the best product choices, including the Exclusive VWR Collection, from premier manufacturers to customers around the globe. We are committed to providing efficient, effective solutions for all your Life Science needs by offering products, service and support that make your work faster, easier and more accurate.

Board of directors and Committee Leadership 2012 B i o c o m B o a r d o f D ir e c t o r s Board Officers and Executive Committee: CHAIR: David Webb, Ph.D., Celgene * VICE CHAIR: Stephen Ferruolo, J.D., Ph.D., USD School of Law * CHAIR ELECT: Magda Marquet, Ph.D., AltheaDX * VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper * VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young * VICE PRESIDENT AND SECRETARY: Carin Canale-Theakston, Canale Communications* VICE PRESIDENT – INDUSTRY: Theodore Schroeder, Cadence Pharmaceuticals, Inc.* PRESIDENT & CEO: Joe Panetta, BIOCOM * Vince Anido, Ph.D., ISTA Pharmaceuticals Martin Birkhofer, M.D., Bristol-Myers Squibb Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Terrence J. Bruggeman, BioTork, LLC Daniel Burgess, Rempex Pharmaceuticals Lawrence Cohn, Stradling Yocca Carlson & Rauth John M. Dunn Geoffrey S. Eich, Amgen M. Wainwright Fishburn, Jr., Cooley LLP * Don Fitzgerald, Genentech Jack Florio, Brinson Patrick Securities Corporation Scott Foote, Square 1 Bank Kieran Gallahue, CareFusion Alan Gold, BioMed Realty Trust Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Jason Hannon, NuVasive Scott Huennekens, Volcano Corporation Guy J. Iannuzzi, 321 Medical Launch Brent D. Jacobs, Cushman & Wakefield David Kabakoff, Ph.D., Sofinnova Ventures Michael Kamdar David Karlman, Otologic Pharmaceutics Richard Kaufman, Foley & Lardner Kevin Larkin, TherOx Harry Leonhardt, Amylin Pharmaceuticals Jack Lief, Arena Pharmaceuticals, Inc. * Jacob Levin, Ph.D., UC Irvine Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc. * William Molloie, PwC Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc. Tina Nova, Ph.D., Genoptix, Inc. A Novartis Company John Parrish, BioVascular, Inc. John C. Reed, M.D., Ph.D., Sanford-Burnham Medical Research Institute Trindl Reeves, Barney & Barney LLC * Herm Rosenman, Gen-Probe, Inc. Theodore D. Roth, Roth Capital Partners LLC Scott Salka James Schaeffer, Ph.D., Merck Research Laboratories* Christophe Schilling, Ph.D., Genomatica, Inc.* Timothy Scott, Pharmatek Laboratories, Inc. Bhasker Shetty, Ph.D.,Pfizer La Jolla Larry Stambaugh, Apercu Partners* Mark Stevenson, Life Technologies * Roger Stoll, Ph.D, Cortex Pharmacueticals Nikki Vogt, Deloitte LLP Scott N. Wolfe, Latham & Watkins Randall E. Woods* Kleanthis Xanthopoulos, Ph.D., Regulus Therapeutics LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects * David Hale, Somaxon Pharmaceuticals * Duane J. Roth, CONNECT

*Executive Committee Members BIOCOM Board Members-Ex-Officio: Ruben Barrales, San Diego Regional Chamber of Commerce David Brenner, M.D., UCSD School of Medicine Mark Cafferty, San Diego Regional Economic Development Corporation Constance Carroll, Ph.D., San Diego Community College District Gary Friedman, The Agouron Institute Catherine Mackey, Ph.D., Mindpiece Partners Peter Preuss, The Preuss Foundation Robert Sullivan, Ph.D., Rady School of Management, UC San Diego

Bi ocom C ommi ttees Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Laboratories, Inc. Education Committee Mike Greig, Pfizer La Jolla Ashley Wildrick, San Diego Workforce Partnership Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield FDA Committee Magda Marquet, Ph.D., AltheaDx Michele Yelmene, Merck Industrial Biotech Committee Lisa Kennedy, Genomatica Lisa Stillwell, Life Technologies Intellectual Property and Patent Law Committee Margaret Dunbar, Sanford-Burnham Medical Research Institute Daniel Hart, Knobbe Martens Olson & Bear LLP Legislative Committee Richard Ledford Jori Tulkki, Gen-Probe, Inc. Medical Device Committee Noel Gillespie, Procopio, Cory, Hargreaves& Savitch Joleen Schultz, 321 Medical Launch Public Policy Oversight Committee* Larry Stambaugh, Apercu Partners Paul Laikind, Sanford-Burnham Medical Research Institute Purchasing Board Committee* Jack Lief, Arena Pharmaceuticals, Inc. Reimbursement and Market Access Committee Michael Pollock, Reynolds Pollock & Associates Scholarship Committee Bente Hansen, BenteHansen and Associates Connie Matsui BIOCOM Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc. *Board level committee

BIOCOM LifeLines Spring 2012

25

BIOCOM MEMBERSHIP Pr e mi u m 321 Medical Launch Alexandria Real Estate Equities American Internet Services Amylin Pharmaceuticals Arena Pharmaceuticals BioMed Realty Trust BioSpace Booz Allen Hamilton BP Biofuels Bristol-Myers Squibb California Manufacturing Technology Consulting Canale Communications Celgene Conatus Pharmaceuticals Cooley Covington & Burling Cushman & Wakefield Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Foley & Lardner Genoptix Gen-Probe Goodwin Procter ISTA Pharmaceuticals KPBS Latham & Watkins Life Technologies Merck Research Laboratories of San Diego Merrill Corporation Mintz, Levin, Cohn, Ferris, Glovsky & Popeo NuVasive Pfizer Global R&D La Jolla PwC SkinMedica TriNet VWR International Wilson Sonsini Goodrich & Rosati

Biotec h n o lo g y Abgent Abide Therapeutics* ACADIA Pharmaceuticals Accugent Laboratories Acris Antibodies ActivX Biosciences Advanced Biomatrix Advanced Targeting Systems ADVENTRX Pharmaceuticals Agradis Aires Pharmaceuticals Akela Pharma AM Chemicals Ambit Biosciences AMBRX American Peptide Company Amgen

Amicrobe* Amplyx Pharmaceuticals AMRI Anaphore AnaptysBio AndroScience Applied Proteomics* Aragon Pharmaceuticals Ardea Biosciences Arrayomics aTyr Pharma Avantgen Aviva Biosciences Bachem Americas BioAtla Biocept BioLegend Biomatrica Biomyx

26 BIOCOM LifeLines Spring 2012

BioNanomatrix BioSciMed BioTork BrainCells Cadence Pharmaceuticals CalAsia Pharmaceuticals CalciMedica Cardinal Specialty Cellana Cell Applications Ceregene Cibus Coda Therapeutics Cortex Pharmaceuticals CovX Research Crucell Biologics Custopharm* Cylene Pharmaceuticals Dart Neuroscience eBioscience Eclipse Therapeutics Elcelyx Therapeutics Electronic BioSciences Elevation Pharmaceuticals Epeius Biotechnologies Excaliard Pharmaceuticals Expression Drug Designs EyeCyte Fabrus Fate Therapeutics Genelux Corporation Gene Therapy Systems Genentech Genomatica GenWay Biotech GlaxoSmithKline Global Bio Therapeutics USA GT Life Sciences GWR Instruments Halozyme Therapeutics Histogen Hitachi Chemical Research Center Huya Bioscience International ICX Biosystems Inception Sciences Inhibrx Integrated DNA Technologies Intellikine International Stem Cell Intrinsic LifeSciences InvivoGen InVivoScribe Technologies ISIS Pharmaceuticals Jaleva Pharmaceuticals Johnson & Johnson Pharmaceutical Research & Development Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company Ligand Pharmaceuticals Lilly Biotechnology Center Lithera Lpath MabVax Therapeutics Marshall Edwards Membrane Receptor Technologies Meritage Pharma Monsanto

Nautilus Environmental Nitto Denko Technical Novartis Pharmaceuticals NovaRx Noven Pharmaceuticals Nucelis* Ocera Therapeutics Octagon Research Solutions Optimer Pharmaceuticals Optimum Therapeutics Orexigen Therapeutics Otologic Pharmaceuticals Otonomy Pacira Pharmaceuticals Pathway Genomics Pfenex Phage Pharmaceuticals Polaris Group PolyPeptide Laboratories Predictive Biology PrimaPharm PrimeGen Biotech Prometheus Laboratories ProSci Incorporated QED Bioscience Receptos Regulus Therapeutics Rempex Pharmaceuticals Renova Therapeutics Ribomed Biotechnologies Roka Bioscience SAFC Pharma Sangart Sanofi-Aventis R&D Santarus Sapient Discovery Senju USA Senomyx Sequel Pharmaceuticals Sequencethree Sequenom SG Biofuels Sherpa Clinical Packaging Siloam Biosciences Somaxon Pharmaceuticals Sorrento Therapeutics Stemgent Stemedica Cell Technologies Synthetic Genomics Takeda San Diego Tanabe Research Laboratories Tocagen Tracon Pharmaceuticals Tragara Pharmaceuticals Transdel Pharmaceuticals Trius Therapeutics Vala Sciences Vasgene Therapeutics Vaxiion Therapeutics Verdezyne Verenium Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Virapur Visionary Pharmaceuticals Wildcat Discovery Technologies* Zacharon Pharmaceuticals Zogenix Zyagen

Medical Device & Diagnostic Accumetrics Advanced BioHealing Aethlon Medical Alphatec Spine AltheaDx Astute Medical Banyan Biomarkers BeneChill BioDx Biological Dynamics BioTech Trading Partners bioTheranostics Breathe Technologies* CareFusion CeloNova Biosciences Cliniqa Critical Diagnostics CTK Biotech CVAC Systems Cytori Therapeutics DermTech International DexCom* Diagnostic Consulting Network Enigma Diagnostics Entra Health Systems Epic Sciences Epitope Diagnostics Fallbrook Engineering Fortimedix USA Freedom Meditech Gaia Medical Institute Glysens Heidelberg Engineering Ichor Medical Systems INOVA Diagnostics* Inovio Biomedical Interventional Spine* Invetech InVision Biomedical Group Ionian Technologies Iris Personalized Medicine KFx Medical LoneStar Heart MARDX Diagnostics Medipacs Micell Technologies NanoImaging Services Naviscan NeoMend* NexDx* OncoSec Medical Organovo PhotoThera Preventice* Qualigen Quantum Design Quidel ResMed REVA Medical Ridge Diagnostics Sirigen SoluLink Biosciences SpectraScience Suneva Medical Tandem Diabetes Targeson TherOx Tristan Technologies

TrovaGene Valor Medical Vantagepoint Laboratory Partners VertiFlex Vertos Medical Volcano Yulex

CRO Abbiotec Absorption Systems Accelagen Accelovance Acurian Advantar Laboratories Agility Clinical Althea Technologies AnaBios Annova Chem Aptuit* Asterand Behavioral Pharma Bend Research Biologics Process Development Califia Bio Cato Research Celula ChemDiv Concortis Biosystems Davos Chemical EastHorn Clinical Services* eStudySite Exon BioSystems Explora BioLabs Hamari Chemical Hungaro Trial CRO* Huntingdon Life Sciences IriSys JadeBio KMC Systems* MedinCell MicroConstants Millenium Laboratories Molecular Response Neox USA NeurAccel Biosciences* NexMed (U.S.A.) Nexus Oncology Novella Clinical Pacific World Discovery PacificGMP Pharmatek Laboratories Prescos Profil Institute for Clinical Research PSI CRO Puracyp Quadrants Scientific RetroVirox Siloam Biosciences Sparta Systems Synteract Tioga Research Toxikon Triligent International Ultimate Labs Velesco Pharmaceutical Services Zenobia Therapeutics

K ey P r ov i d e r Airgas Bloomberg Government Enterprise Partners Venture Capital Harlan Laboratories KPMG Oracle Procopio,Cory, Hargreaves & Savitch Qualcomm San Diego Gas & Electric

P r ov i d e r 2Connect 360 Vantage ACT Litigation Services Advantar Laboratories Aerotek Alliant Insurance AMN Healthcare Aubrey Group Audacity Avantor Performance Materials* Barney & Barney Beckloff Associates Bente Hansen & Associates Bingham McCutchen Biocair Biohit BioSurplus Biotech Primer Biotech Vendor Services BioTix Birch, Stewart, Kolasch & Birch Brinson Patrick Securities Caliber Associates Campbell Alliance Capsugel, Americas Region Cassidy Turley CB Richard Ellis China Business Partners Chubb Group of Insurance Companies Clarkston Consulting Cleartrial Clinigen Pharma Collins Development Company CryoPort Cymer Degenkolb Engineers* Domain Associates Dorsey & Whitney DPR Construction Dr. Reddy’s Laboratories EBD Group Enterey Fabiani & Company Ferguson Pape Baldwin Architects Fish & Richardson P.C. Fitzpatrick, Cella, Harper & Scinto Forward Ventures Global BioPharm Executive Search Global Language Solutions Good & Roberts, Inc. General Contractors

Gordon & Rees Grande Colonial Grant Thornton Greiner Bio-One HCP Life Science Estate Hooper, Lundy & Bookman Hughes Marino Hyatt Regency La Jolla at Aventine Innovative Lease Services* InVenios* InXpress Iron Mountain Information Management Irving Group Kelly Scientific Resources Kilroy Realty Knobbe, Martens, Olson & Bear Kronos Leadership Edge Lilly Ventures McKenna Long & Aldridge Medpoint* Mentara Michael Ehrenfeld Company Morgan, Lewis & Bockius Morrison & Foerster Moss Adams NOVA Biologics Occupational Services Office Depot OmniComm Systems* On Call Staffing Solutions Oxford Finance Pegasus Cleanroom Services Phillips Plastics Corporation Prevost Construction PR Newswire Project Management Advisors Prudential Cleanroom Services Q5 Group QuakeHOLD! Industrial Relocation Coordinates Retirement DNA Roth Capital Partners RS Calibration Services Russo Partners Salient Networks Sanford Rose Associates Scisive Consulting ShareVault* Sharp Business Systems Sheppard Mullin Richter & Hampton Shred-it Shred San Diego* Silicon Valley Bank SLM Contract Furniture* Smart Source* Snell & Wilmer* Sofinnova Ventures Sonceboz* SourceOne Square 1 Bank Stradling Yocca Carlson & Rauth Stria Studley Sughrue Mion PLLC Sullivan United Moving & Storage Technical Safety Services The Business Cleaning

Company* The Sandler Group* Thomas, Mcnerney & Partners The Irving Group United Parcel Service (UPS) Vantage Point Advisors Veolia Versant Ventures Waste Management Healthcare Solutions Wells Fargo Insurance Services Wind River Systems Witt Kieffer* Your Bio Team ZS Associates

Non-P rofi t American Cancer Society, Border Sierra Region Brandman University CA Institute for Regenerative Medicine California State University, San Marcos City of Murrieta City of Temecula Combined Health Agencies CONNECT Consulate of Canada Human BioMolecular Research Institute Institute of Engineering in Medicine ISM San Diego J. Craig Venter Institute La Jolla Bioengineering Institute La Jolla Infectious Disease Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center LSIT Global Institute MiraCosta College Biotech Program Mt. San Jacinto College National University PhRMA Point Loma Nazarene University PRISM Rady School of Management, UCSD Salk Institute for Biological Studies, The San Diego Clinical Translational Research Institute, UCSD San Diego Community College District San Diego Convention & Visitors Bureau San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp.

San Diego Natural History Museum San Diego Workforce Partnership San Diego World Trade Center San Diego Zoo Global Sanford-Burnham Medical Research Institute

Scripps Health Scripps Research Institute, The Scottish Development International SDSU, CSUPERB Program Swedish American Chamber of Commerce San Diego The BioIndustry Association Torrey Pines Institute for Molecular Studies UC Irvine, Office of Technology Alliances UCI, Office of Research UCSD, Department of Bioengineering UCSD External Relations Office UC San Diego Extension UCSD School of Medicine UCSD, Technology Transfer Office UK Trade & Investment University of San Diego Vaccine Research Institute of San Diego

Indi vi dual Antoinette Azevedo Bernard King Elliot Parks Gary Friedman Julie Ames Michael Pollock Nicholas Maczkov Peter Preuss Richard Ledford Walter J. Bochenko

* New Member as of May 2012

BIOCOM LifeLines Spring 2012

27

Prsrt Std U.S. Postage PAID Permit #2325 San Diego, CA

4510 Executive Drive Plaza One San Diego, CA 92121-3021 858.455.0300 Fax 858.455.0022 www.biocom.org

Step Into the Future of Life Sciences — We Are Already There

• • • • • • •

ADMET Process Biostatistics Biotechnology Manufacturing Biotechnology Project Management Business of Biotech Clinical Trials Diagnostics

• • • • • •

Drug Discovery and Development Genomics Life Sciences IT Medicinal Chemistry Quality Assurance and Control Regulatory Affairs

(858) 534-9353 | unexbio@ucsd.edu | extension.ucsd.edu/lifesciences

SP11-4057

UC San Diego Extension’s Life Sciences department offers a broad array of courses and certificate programs to meet the continuing education needs of the Life Sciences community. The programs support high-level skill development for industry professionals and career transition for those interested in entering the field.